GPT and metabolic dysfunction-associated steatotic liver disease: The need for biopsies was reduced by selecting patients based on insulin resistance (42 biopsies per 100 screened patients), presence of diabetes (56 biopsies per 100 screened patients), presence of NAFLD (54 biopsies per 100 screened patients), or abnormal ALT (50 biopsies per 100 screened patients).